RxDoctor Payments Data

Christopher Yardan, DPM

Podiatrist · Wallingford, CTNPI 1972866275

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Smith+Nephew at 57.2% of the total. Reporting peaked in 2022 at $4,154 and has fallen 92.7% since, to $304 in 2025. Among podiatrist clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,138in general payments, 2019–2025

Across 85 payments — averaging $95.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$5K
  • Gramercy Extremity Orthopedics LLC$3K
  • Paratek Pharmaceuticals, Inc.$171
  • Integra Lifesciences Corporation$121
  • Bioventus LLC$74
  • Orthofix Medical, Inc.$68
  • plus $491 from 18 others
$70,000in ownership & investment interests, 2019–2025

Across 6 payments — averaging $11,667 each. An ownership or investment interest held by the physician or an immediate family member.

  • Gramercy Extremity Orthopedics LLC$70K

What the payments were for

  • Consulting fees$2,25028%
  • Speaking & faculty fees$3,40842%
  • Travel & lodging$1362%
  • Food & beverage$2,34529%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,138 in reported general payments places this provider in the 90th percentile of 119 podiatrist providers in Connecticut.

See all podiatrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$52,282
Medicare patients
131
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin36$278
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$129
Methylprednisolone18$125
Meloxicam18$21

Paid to pharmacies, not to this prescriber.

Other podiatrist in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →